	US 12,286,474 B2
	Anti-CD38 antibodies for treatment of acute myeloid leukemia
Parul Doshi, Chester Springs, PA (US); Gwenn Danet-Desnoyers, Philadelphia, PA (US); Cedric Dos Santos, San Bruno, CA (US); Amy Sasser, Doylestown, PA (US); and Xiaochuan Shan, Philadelphia, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Aug. 27, 2020, as Appl. No. 17/005,039.
Application 17/005,039 is a continuation of application No. 14/956,890, filed on Dec. 2, 2015, granted, now 10,793,630.
Claims priority of provisional application 62/087,442, filed on Dec. 4, 2014.
Prior Publication US 2021/0047401 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/704 (2006.01); A61K 31/706 (2006.01); A61K 31/7068 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 31/704 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61N 5/1027 (2013.01); A61N 5/1045 (2013.01); A61N 5/1084 (2013.01); C07K 16/2896 (2013.01); A61K 39/001126 (2018.08); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)]

12 Claims

1. A method of treating relapsed or refractory acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject an anti-CD38 antibody:

b) for a time sufficient to treat the relapsed or refractory AML, wherein the anti-CD38 antibody consists of daratumumab, and wherein the AML is AML with at least one mutation in a gene selected from the group consisting of fms-related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), isocitrate dehydrogenase 2 (IDH2), DNA (cytosine-5) methyltransferase 3 (DNMT3A) and CCAAT/enhancer binding protein alpha (CEBPA).